These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 27982602)
1. Targeted Biomimetic Nanoparticles for Synergistic Combination Chemotherapy of Paclitaxel and Doxorubicin. Rui M; Xin Y; Li R; Ge Y; Feng C; Xu X Mol Pharm; 2017 Jan; 14(1):107-123. PubMed ID: 27982602 [TBL] [Abstract][Full Text] [Related]
2. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells. Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697 [TBL] [Abstract][Full Text] [Related]
3. Natural Particulates Inspired Specific-Targeted Codelivery of siRNA and Paclitaxel for Collaborative Antitumor Therapy. Wang R; Zhao Z; Han Y; Hu S; Opoku-Damoah Y; Zhou J; Yin L; Ding Y Mol Pharm; 2017 Sep; 14(9):2999-3012. PubMed ID: 28753317 [TBL] [Abstract][Full Text] [Related]
4. Ratiometric co-encapsulation and co-delivery of doxorubicin and paclitaxel by tumor-targeted lipodisks for combination therapy of breast cancer. Feng C; Zhang H; Chen J; Wang S; Xin Y; Qu Y; Zhang Q; Ji W; Yamashita F; Rui M; Xu X Int J Pharm; 2019 Apr; 560():191-204. PubMed ID: 30769131 [TBL] [Abstract][Full Text] [Related]
5. Lysosome-Independent Intracellular Drug/Gene Codelivery by Lipoprotein-Derived Nanovector for Synergistic Apoptosis-Inducing Cancer-Targeted Therapy. Wang W; Chen K; Su Y; Zhang J; Li M; Zhou J Biomacromolecules; 2018 Feb; 19(2):438-448. PubMed ID: 29334216 [TBL] [Abstract][Full Text] [Related]
6. Construction of a biodegradable, versatile nanocarrier for optional combination cancer therapy. Wen J; Lv Y; Xu Y; Zhang P; Li H; Chen X; Li X; Zhang L; Liu F; Zeng W; Sun S Acta Biomater; 2019 Jan; 83():359-371. PubMed ID: 30414486 [TBL] [Abstract][Full Text] [Related]
7. Coloaded Nanoparticles of Paclitaxel and Piperlongumine for Enhancing Synergistic Antitumor Activities and Reducing Toxicity. Liu Q; Zhao D; Zhu X; Chen H; Yang Y; Xu J; Zhang Q; Fan A; Li N; Guo C; Kong Y; Lu Y; Chen X J Pharm Sci; 2017 Oct; 106(10):3066-3075. PubMed ID: 28552690 [TBL] [Abstract][Full Text] [Related]
8. Simultaneous delivery of anti-miR21 with doxorubicin prodrug by mimetic lipoprotein nanoparticles for synergistic effect against drug resistance in cancer cells. Rui M; Qu Y; Gao T; Ge Y; Feng C; Xu X Int J Nanomedicine; 2017; 12():217-237. PubMed ID: 28115844 [TBL] [Abstract][Full Text] [Related]
9. Folate-targeted polymersomes loaded with both paclitaxel and doxorubicin for the combination chemotherapy of hepatocellular carcinoma. Zhu D; Wu S; Hu C; Chen Z; Wang H; Fan F; Qin Y; Wang C; Sun H; Leng X; Kong D; Zhang L Acta Biomater; 2017 Aug; 58():399-412. PubMed ID: 28627436 [TBL] [Abstract][Full Text] [Related]
10. Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier. Yuan Y; Wang W; Wang B; Zhu H; Zhang B; Feng M J Drug Target; 2013 May; 21(4):367-74. PubMed ID: 23600747 [TBL] [Abstract][Full Text] [Related]
11. A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: preparation, in vitro and in vivo evaluation. Li Q; Lv S; Tang Z; Liu M; Zhang D; Yang Y; Chen X Int J Pharm; 2014 Aug; 471(1-2):412-20. PubMed ID: 24905776 [TBL] [Abstract][Full Text] [Related]
12. Co-delivery of doxorubicin and paclitaxel by PEG-polypeptide nanovehicle for the treatment of non-small cell lung cancer. Lv S; Tang Z; Li M; Lin J; Song W; Liu H; Huang Y; Zhang Y; Chen X Biomaterials; 2014 Jul; 35(23):6118-29. PubMed ID: 24794923 [TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor effect of folate-targeted Pluronic™ F-127/poly(lactic acid) polymersomes for codelivery of doxorubicin and paclitaxel. Wu TY; Li ZL; Gong YC; Xiong XY Nanomedicine (Lond); 2023 Feb; 18(5):455-469. PubMed ID: 37166001 [TBL] [Abstract][Full Text] [Related]
14. Application of a lipid-coated hollow calcium phosphate nanoparticle in synergistic co-delivery of doxorubicin and paclitaxel for the treatment of human lung cancer A549 cells. Wu C; Xu J; Hao Y; Zhao Y; Qiu Y; Jiang J; Yu T; Ji P; Liu Y Int J Nanomedicine; 2017; 12():7979-7992. PubMed ID: 29184399 [TBL] [Abstract][Full Text] [Related]
15. A synergistic combination therapy with paclitaxel and doxorubicin loaded micellar nanoparticles. Wang Y; Ma S; Xie Z; Zhang H Colloids Surf B Biointerfaces; 2014 Apr; 116():41-8. PubMed ID: 24441457 [TBL] [Abstract][Full Text] [Related]
17. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment. Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310 [TBL] [Abstract][Full Text] [Related]
18. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy. Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609 [TBL] [Abstract][Full Text] [Related]
19. Co-delivery of Pirarubicin and Paclitaxel by Human Serum Albumin Nanoparticles to Enhance Antitumor Effect and Reduce Systemic Toxicity in Breast Cancers. Yi X; Lian X; Dong J; Wan Z; Xia C; Song X; Fu Y; Gong T; Zhang Z Mol Pharm; 2015 Nov; 12(11):4085-98. PubMed ID: 26422373 [TBL] [Abstract][Full Text] [Related]
20. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer. Jiang C; Wang X; Teng B; Wang Z; Li F; Zhao Y; Guo Y; Zeng Q ACS Appl Mater Interfaces; 2021 Aug; 13(30):35248-35265. PubMed ID: 34284582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]